-Reuters
Related Posts
G1 Therapeutics Presents Phase 1 Data At ASCO Describing ‘Favorable Safety Profile and Evidence Of Antitumor Activity Of Rintodestrant Combined With Palbociclib In Patients With ER+/HER2- Advanced Breast Cancer’
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results from its Phase 1 study of its oral selective estrogen receptor degrader (SERD), rintodestrant,
Despite Seeing Accelerated 2023 Growth, This Analyst Cut Penumbra’s Price Target – Here’s Why
Penumbra Inc (NYSE:PEN) reported Q1 sales that beat Street expectations, driven by Vascular upside, and reiterated its 2022 revenue guidance. Wells…
B. Riley Securities Initiates Coverage On Hyperfine with Buy Rating, Announces Price Target of $3.5
B. Riley Securities analyst Neil Chatterji initiates coverage on Hyperfine (NASDAQ:HYPR) with a Buy rating and announces Price Target of $3.5.